TrialThe Lancet. Infectious diseases2022

Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials.

Gang Zeng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.